Live Market News

Schechter Investment Advisors LLC Makes New Investment in Teva



Schechter Investment Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 11,185 shares of the company’s stock, valued at approximately $117,000.

A number of other large investors have also recently bought and sold shares of the business. Money Concepts Capital Corp acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its stake in Teva Pharmaceutical Industries by 1,729.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock valued at $39,000 after purchasing an additional 3,580 shares during the last quarter. Signaturefd LLC boosted its stake in Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock valued at $51,000 after purchasing an additional 2,394 shares during the last quarter. UniSuper Management Pty Ltd acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $57,000. Finally, Natixis acquired a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $61,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TEVA shares. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price target for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Finally, Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.78.

View Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Trading Down…

Latest Market News
1 of 94



Read More: Schechter Investment Advisors LLC Makes New Investment in Teva

Leave a comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.